NEW YORK, June 08, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies") (NASDAQ:ITCI) between August 12, 2014 and April 28, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-sb/intra-cellular-therapies-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
If you suffered a loss in Intra-Cellular Therapies you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 



